Anti‐myeloma potential of ruxolitinib in co‐existing <i>JAK2V617F</i>‐positive smouldering myeloma and polycythaemia vera

Lee, Holly; McCulloch, Sylvia; Mahé, Etienne; Shafey, Mona; Rashid-Kolvear, Fariborz; Khan, Faisal; Prajapati, Dwip; Neri, Paola; Duggan, Peter; Tay, Jason; Bahlis, Nizar J.; Jiménez-Zepeda, Victor H

doi:10.1111/bjh.16533

Cited by 4 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study analyzed two different patients both diagnosed with JAK2 mutation positive PCV and each later developed smoldering myeloma. Interestingly, the JAK2 V617F mutation was detected in the bone marrow plasma cells of these two patients as well, suggesting a single driver mutation for both the plasma cell and erythrocyte proliferations in these cases [ 11 ]. It is possible that patients with concurrent PCV and MM have a common pluripotent hematopoietic stem cell dysfunction causing proliferative diseases in both myeloid and lymphoid cell lines [ 10 , 12 ].…”

Section: Discussionmentioning

confidence: 99%

A Rare Coexistence of Multiple Myeloma and Polycythemia Vera

Landsman,

Barua,

Podrumar

2023

J Hematol

View full text Add to dashboard Cite

Multiple myeloma (MM) is classically associated with organ dysfunction leading to hypercalcemia, renal insufficiency, anemia and bone disease, known as the CRAB criteria. More than 70% of patients with MM present with anemia. Few rare case reports, however, have demonstrated the presentation of MM associated with polycythemia. We present an interesting case of a 65-year-old female who was initially diagnosed with monoclonal gammopathy of undetermined significance (MGUS) which progressed to smoldering myeloma and later developed into MM. The patient also had coexisting polycythemia vera (PCV). We discuss the typical patient presentations as well as the expanded diagnostic criteria for MM. The pathophysiology explaining the coexistence of polycythemia and MM will be explored as well.

show abstract

Section: Discussionmentioning

confidence: 99%

A Rare Coexistence of Multiple Myeloma and Polycythemia Vera

Landsman,

Barua,

Podrumar

2023

J Hematol

View full text Add to dashboard Cite

show abstract

“…The coexistence of MM and PV is rare, 1 , 2 , 3 , 4 , 5 , 6 and the treatment of MM under these conditions has not been described in detail. MM was previously considered an incurable hematologic neoplasm, with patients rarely achieving complete remission with alkylating reagents and steroids.…”

Section: Discussionmentioning

confidence: 99%

“… 21 Recently, MM and MPN clones were directly analyzed in patients with JAK2 mutations, a characteristic acquired mutation found in patients with MPN. 22 Lee et al 6 demonstrated JAK2 mutations in both myeloid and CD138‐sorted plasma cells of two patients with smoldering MM associated with JAK2 mutation‐positive PV, suggesting shared stem cell progenitors of MM and PV. Conversely, Kuroda et al 23 reported that the plasma cell fraction was negative for JAK2 mutations in a patient with MM associated with JAK2‐positive essential thrombocythemia, another type of MPN, suggesting different origins in their patient.…”

Section: Discussionmentioning

confidence: 99%

“…Maeda and Abraham reported on patients with coexisting MM and PV, comprehensively summarizing 11 cases reported before 1984 2 ; however, few cases have been documented in recent years. 3 , 4 , 5 , 6 In Japan, such reports are uncommon. 7 Most patients have smoldering myeloma, and no precise treatment approach has been identified.…”

Section: Introductionmentioning

confidence: 99%

“…The coexistence of multiple myeloma (MM) and polycythemia vera (PV) was first described by Lawrence and Rosenthal in 1948 1 ; however, subsequent cases have been sporadically reported. Maeda and Abraham reported on patients with coexisting MM and PV, comprehensively summarizing 11 cases reported before 1984 2 ; however, few cases have been documented in recent years 3–6 . In Japan, such reports are uncommon 7 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Development of multiple myeloma after 15 years of treatment for polycythemia vera and successful treatment using bortezomib: A case report

Kimura¹,

Furukawa²,

Mori³

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma

Zhou

Chng

2022

Cells

View full text Add to dashboard Cite

Multiple myeloma (MM) is the second most common hematological malignancy, characterized by an abnormal accumulation of plasma cells in the bone marrow. Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that modulates the transcription of multiple genes to regulate various principal biological functions, for example, cell proliferation and survival, stemness, inflammation and immune responses. Aberrant STAT3 activation has been identified as a key driver of tumorigenesis in many types of cancers, including MM. Herein, we summarize the current evidence for the role of STAT3 in affecting cancer hallmark traits by: (1) sustaining MM cell survival and proliferation, (2) regulating tumor microenvironment, (3) inducing immunosuppression. We also provide an update of different strategies for targeting STAT3 in MM with special emphasis on JAK inhibitors that are currently undergoing clinical trials. Finally, we discuss the challenges and future direction of understanding STAT3 signaling in MM biology and the clinical development of STAT3 inhibitors.

show abstract

Anti‐myeloma potential of ruxolitinib in co‐existing JAK2V617F‐positive smouldering myeloma and polycythaemia vera

Cited by 4 publications

References 21 publications

A Rare Coexistence of Multiple Myeloma and Polycythemia Vera

A Rare Coexistence of Multiple Myeloma and Polycythemia Vera

Development of multiple myeloma after 15 years of treatment for polycythemia vera and successful treatment using bortezomib: A case report

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma

Contact Info

Product

Resources

About